title: Lymphadenectomy exacerbates tumor growth while lymphadenectomy plus the adoptive transfer of autologous cytotoxic cells and low-dose cyclophosphamide induces regression of an established murine fibrosarcoma.
abstract: Tumor-draining lymph node (TDLN) ablation is routinely performed in the management of cancer; nevertheless, its usefulness is at present a matter of debate. TDLN are central sites where T cell priming to tumor antigens and onset of the antitumor immune response occur. However, tumor-induced immunosuppression has been demonstrated at TDLN, leading to downregulation of antitumor reaction and tolerance induction. Tolerance in turn is a main impairment for immunotherapy trials. We used a murine immunogenic fibrosarcoma that evolves to a tolerogenic state, to study the cellular and molecular mechanisms underlying tolerance induction at the level of TDLN and to design an appropriate immunotherapy. We determined that following a transient activation, the established tumor induces signs of immunosuppression at TDLN that coexist with local and systemic evidences of antitumor response. Therefore, we evaluated the feasibility of removing TDLN in order to eliminate a focus of immunosuppression and favor tumor rejection; but instead, a marked exacerbation of tumor growth was induced. Combining TDLN ablation with the in vivo depletion of regulatory cells by low-dose cyclophosphamide and the restoring of the TDLN-derived cells into the donor mouse by adoptive transference, resulted in lowered tumor growth, enhanced survival and a considerable degree of tumor regression. Our results demonstrate that important antitumor elements can be eliminated by lymphadenectomy and proved that the concurrent administration of low-dose chemotherapy along with the reinoculation of autologous cytotoxic cells provides protection. We suggest that this protocol may be useful, especially in the cases where lymphadenectomy is mandatory.
authors.affiliation: División Medicina Experimental, Academia Nacional de Medicina de Buenos Aires, ILEX-CONICET, Buenos Aires, Argentina.
authors.forename: Andrea
authors.initials: A
authors.lastname: Maglioco
authors.forename: Damián
authors.initials: D
authors.lastname: Machuca
authors.forename: Juliana
authors.initials: J
authors.lastname: Mundiñano
authors.forename: Gabriel
authors.initials: G
authors.lastname: Cabrera
authors.forename: Gabriela
authors.initials: G
authors.lastname: Camicia
authors.forename: Juan
authors.initials: J
authors.lastname: Bruzzo
authors.forename: Gabriela
authors.initials: G
authors.lastname: Camerano
authors.forename: Héctor
authors.initials: H
authors.lastname: Costa
authors.forename: Raúl A
authors.initials: RA
authors.lastname: Ruggiero
authors.forename: Graciela I
authors.initials: GI
authors.lastname: Dran
mesh_terms: D019264:Adoptive Transfer; D000818:Animals; D018906:Antineoplastic Agents, Alkylating / Q000627:therapeutic use*; D003131:Combined Modality Therapy; D003520:Cyclophosphamide / Q000627:therapeutic use*; D005354:Fibrosarcoma / Q000188:drug therapy / Q000628:therapy*; D016219:Immunotherapy, Adoptive; D008197:Lymph Node Excision; D008297:Male; D051379:Mice; D008807:Mice, Inbred BALB C; D008810:Mice, Inbred C57BL; D013602:T-Lymphocytes, Cytotoxic / Q000276:immunology / Q000637:transplantation*
chemical_list: D018906:Antineoplastic Agents, Alkylating; D003520:Cyclophosphamide